A Phase I study of expanded and activated allogeneic gamma-delta T cells for patients with blood cancers following haploidentical stem cell transplantation.

Trial Profile

A Phase I study of expanded and activated allogeneic gamma-delta T cells for patients with blood cancers following haploidentical stem cell transplantation.

Planning
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs Allogeneic-gamma-delta-T-cell-therapy (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Oct 2017 According to an Incysus media release, the US FDA has approved the INDA application for this trial. Acceptance of this IND enables Incysus and the University of Alabama at Birmingham (UAB) to initiate a clinical program to test the safety and activity of an allogeneic gamma delta T-cell-therapy.
    • 21 Sep 2017 New trial record
    • 19 Sep 2017 According to an Incysus media release, company has submitted Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top